About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Jak2tm1(JAK2)Argr
targeted mutation 1, Anthony R Green
MGI:4836590
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Jak2tm1(JAK2)Argr/Jak2+
Tg(Mx1-cre)1Cgn/0
involves: 129S7/SvEvBrd * C57BL/6 * CBA MGI:4836619


Genotype
MGI:4836619
cn1
Allelic
Composition
Jak2tm1(JAK2)Argr/Jak2+
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: 129S7/SvEvBrd * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Jak2tm1(JAK2)Argr mutation (0 available); any Jak2 mutation (5 available)
Tg(Mx1-cre)1Cgn mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• at 6 and 26 weeks following pIpC administration, the number of pro-erythrocytes and terminally differentiated erythroblasts is increased compared to in wild-type mice (J:164539)
• at 6 and 26 weeks following pIpC administration, the number of pro-erythrocytes and terminally differentiated erythroblasts is increased compared to in wild-type mice (J:164539)
• in one mouse following pIpC administration (J:164539)
• in one mouse following pIpC administration (J:164539)
• following pIpC administration,10% of mice exhibit increase in Ter119+ erythroid cells in bone marrow (BM), CD71+Ter119+ erythroid cells in the spleen, and Mac1+Gr1+ cells in BM and spleen compared with wild-type mice (J:164539)
• following pIpC administration, one mouse exhibited granulocytic hyperplasia, patchy accumulation of immature cells, reduction of erythroid and megakaryocytic cells, development of collagen fibrosis, decreased Ter119+ erythroid cells in BM, increased CD71+Ter119+ erythroid cells in the spleen, and increased Mac1+Gr1+ cells in BM and spleen compared with wild-type mice (J:164539)
• following pIpC administration,10% of mice exhibit increase in Ter119+ erythroid cells in bone marrow (BM), CD71+Ter119+ erythroid cells in the spleen, and Mac1+Gr1+ cells in BM and spleen compared with wild-type mice (J:164539)
• following pIpC administration, one mouse exhibited granulocytic hyperplasia, patchy accumulation of immature cells, reduction of erythroid and megakaryocytic cells, development of collagen fibrosis, decreased Ter119+ erythroid cells in BM, increased CD71+Ter119+ erythroid cells in the spleen, and increased Mac1+Gr1+ cells in BM and spleen compared with wild-type mice (J:164539)
• 26 weeks following pIpC administration, the number of Gr+Mac1+ cells is modestly increased compared to in wild-type mice (J:164539)
• 10 weeks after pIpC treatment, bone marrow cells exposed to thrombopoietin (TPO) exhibit increased number of ploidy CD41+ cells compared with similarly treated wild-type cells (J:164539)
• 26 weeks following pIpC administration, the number of Gr+Mac1+ cells is modestly increased compared to in wild-type mice (J:164539)
• 10 weeks after pIpC treatment, bone marrow cells exposed to thrombopoietin (TPO) exhibit increased number of ploidy CD41+ cells compared with similarly treated wild-type cells (J:164539)
• 6 weeks, but not 26 weeks, after pIpC treatment, mice exhibit increased bone marrow-derived colony-forming units-granulocyte, colony-forming units-macrophage, and colony forming units granulocyte-macrophage (CFU-GM) compared with wild-type mice (J:164539)
• however, no TPO-independent megakaryocyte colonies are observed (J:164539)
• 6 weeks, but not 26 weeks, after pIpC treatment, mice exhibit increased bone marrow-derived colony-forming units-granulocyte, colony-forming units-macrophage, and colony forming units granulocyte-macrophage (CFU-GM) compared with wild-type mice (J:164539)
• however, no TPO-independent megakaryocyte colonies are observed (J:164539)
• at 6 and 26 weeks following pIpC administration, mice exhibit megakaryocytic hyperplasia with large and hyperlobated forms unlike in wild-type mice (J:164539)
• at 6 and 26 weeks following pIpC administration, mice exhibit megakaryocytic hyperplasia with large and hyperlobated forms unlike in wild-type mice (J:164539)
• modestly at 6 weeks after pIpC treatment in the presence or absence of erythropoietin (EPO) (J:164539)
• significant at 26 weeks after pIpC and EPO treatment with an increase in EPO-independent BFU-E at 26 weeks (J:164539)
• modestly at 6 weeks after pIpC treatment in the presence or absence of erythropoietin (EPO) (J:164539)
• significant at 26 weeks after pIpC and EPO treatment with an increase in EPO-independent BFU-E at 26 weeks (J:164539)
• in 10% of mice following pIpC administration (J:164539)
• in 10% of mice following pIpC administration (J:164539)
• in 10% of mice following pIpC administration (J:164539)
• in 10% of mice following pIpC administration (J:164539)
• following pIpC administration (J:164539)
• following pIpC administration (J:164539)
• following pIpC administration (J:164539)
• following pIpC administration (J:164539)
• in one mouse following pIpC administration (J:164539)
• in one mouse following pIpC administration (J:164539)
• following pIpC administration (J:164539)
• following pIpC administration (J:164539)
• after pIpC treatment, mice exhibit reduced numbers of LSK cells compared with wild-type mice (J:164539)
• after pIpC treatment, mice exhibit reduced numbers of LSK cells compared with wild-type mice (J:164539)
• in 10% of mice following pIpC administration (J:164539)
• in 10% of mice following pIpC administration (J:164539)
• after pIpC treatment, LSK cells exhibit increased DNA damage, reduced cell cycling, and reduced apoptosis compared with wild-type mice (J:164539)
• in transplantation assays, hematopoietic stem cells from pIpC treated mice exhibits impaired long-term repopulation compared with wild-type cells (J:164539)
• after pIpC treatment, LSK cells exhibit increased DNA damage, reduced cell cycling, and reduced apoptosis compared with wild-type mice (J:164539)
• in transplantation assays, hematopoietic stem cells from pIpC treated mice exhibits impaired long-term repopulation compared with wild-type cells (J:164539)

immune system
• in one mouse following pIpC administration (J:164539)
• in one mouse following pIpC administration (J:164539)
• following pIpC administration (J:164539)
• following pIpC administration (J:164539)
• in 10% of mice following pIpC administration (J:164539)
• in 10% of mice following pIpC administration (J:164539)

skeleton
• following pIpC administration,10% of mice exhibit bone marrow fibrosis unlike wild-type mice (J:164539)
• following pIpC administration,10% of mice exhibit bone marrow fibrosis unlike wild-type mice (J:164539)

cellular
• 26 weeks following pIpC administration, the number of Gr+Mac1+ cells is modestly increased compared to in wild-type mice (J:164539)
• 10 weeks after pIpC treatment, bone marrow cells exposed to thrombopoietin (TPO) exhibit increased number of ploidy CD41+ cells compared with similarly treated wild-type cells (J:164539)
• 26 weeks following pIpC administration, the number of Gr+Mac1+ cells is modestly increased compared to in wild-type mice (J:164539)
• 10 weeks after pIpC treatment, bone marrow cells exposed to thrombopoietin (TPO) exhibit increased number of ploidy CD41+ cells compared with similarly treated wild-type cells (J:164539)

Mouse Models of Human Disease
OMIM ID Ref(s)
Thrombocythemia 1; THCYT1 187950 J:164539





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory